University Of Maryland, Baltimore

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1807-01-01

Employees: 7.3K

Market Cap: -

Website: http://www.umaryland.edu

Clinical Trials

Adjunctive Treatment for Decreasing Symptoms of Schizophrenia

Phase 2

Completed

Conditions: Schizophrenia
Schizoaffective Disorder

First Posted Date: 2005-09-22

Last Posted Date: 2019-08-20

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 240

Registration Number: NCT00222235

Locations: 🇺🇸
Maryland Psychiatric Research Center, Baltimore, Maryland, United States
🇮🇱
Ezrath Nashim Association, Sarah Herzog Memorial Hospital, Jerusalem, Israel
🇺🇸
UCLA/VA Greater Los Angeles Health Care System, Los Angeles, California, United States

and more 2 locations

Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia

Phase 4

Completed

Conditions: Schizoaffective Disorder
Schizophrenia

Interventions: Drug: galantamine

First Posted Date: 2005-09-15

Last Posted Date: 2020-12-16

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 117

Registration Number: NCT00176423

Locations: 🇺🇸
Maryland Psychiatric Research Center, Baltimore, Maryland, United States

A Comparison of Bupropion SR and Placebo for Smoking Cessation

Phase 4

Completed

Conditions: Tobacco Use Disorder

Interventions: Drug: Placebo Oral Tablet
Drug: Bupropion SR

First Posted Date: 2005-09-15

Last Posted Date: 2019-08-16

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 52

Registration Number: NCT00176449

Locations: 🇺🇸
Maryland Psychiatric REsearch Center, Catonsville, Maryland, United States

Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients

Phase 4

Completed

Conditions: Schizophrenia

Interventions: Behavioral: Diet support group
Behavioral: Group counseling and exercise

First Posted Date: 2005-09-15

Last Posted Date: 2022-03-14

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 40

Registration Number: NCT00176436

Locations: 🇺🇸
Maryland Psychiatric Research Center, Catonsville, Maryland, United States

New Antipsychotic Strategies: Quetiapine and Risperidone vs. Fluphenazine in Treatment Resistant Schizophrenia

Phase 3

Completed

Conditions: Schizophrenia

First Posted Date: 2005-09-12

Last Posted Date: 2019-08-19

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 150

Registration Number: NCT00161018

Locations: 🇺🇸
Maryland Psychiatric Research Center, Catonsville, Maryland, United States

An Open-Label Investigation of the Adjuvant Therapeutic Effects of Galantamine in Patients With Chronic Schizophrenia and Persistent Deficit Symptoms

Not Applicable

Completed

Conditions: Chronic Schizophrenia

First Posted Date: 2005-09-12

Last Posted Date: 2022-03-17

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 20

Registration Number: NCT00161044

Locations: 🇺🇸
Maryland Psychiatric Research Center, Catonsville, Maryland, United States

Atomoxetine as an Adjunct to Novel Antipsychotic Medication in the Treatment of Cognitive Deficits of Schizophrenia

Not Applicable

Completed

Conditions: Schizophrenia

First Posted Date: 2005-09-12

Last Posted Date: 2019-08-19

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 30

Registration Number: NCT00161031

Locations: 🇺🇸
Veterans Affairs Maryland Health Care System, Baltimore, Maryland, United States
🇺🇸
Maryland Psychiatric Research Center, Catonsville, Maryland, United States

Electrophysiological Effects of Late PCI After MI

Not Applicable

Completed

Conditions: Cardiovascular Diseases
Heart Diseases
Myocardial Infarction
Coronary Disease
Arrhythmia
Ventricular Fibrillation

Interventions: Procedure: PCI
Drug: Optimal Medical Therapy

First Posted Date: 2005-07-14

Last Posted Date: 2022-05-18

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 300

Registration Number: NCT00119847

Locations: 🇺🇸
Stony Brook University Medical Center, Stony Brook, New York, United States

Improving Cardiovascular Treatment Approaches Among Minorities

Completed

Conditions: Cardiovascular Diseases
Hypertension
Heart Diseases
Diabetes Mellitus

First Posted Date: 2005-01-11

Last Posted Date: 2021-05-11

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 823

Registration Number: NCT00101478

Locations: 🇺🇸
University of Maryland Baltimore, Baltimore, Maryland, United States
🇺🇸
Bon Secours Hospital, Baltimore, Maryland, United States

R115777 in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia

Phase 1

Completed

Conditions: Leukemia

First Posted Date: 2004-08-27

Last Posted Date: 2019-11-07

Lead Sponsor: University of Maryland, Baltimore

Registration Number: NCT00004009

Locations: 🇺🇸
University of Iowa College of Medicine, Iowa City, Iowa, United States
🇺🇸
University of Rochester Cancer Center, Rochester, New York, United States
🇺🇸
Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy